GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Deferred Policy Acquisition Costs

AVEO Pharmaceuticals (STU:VPA1) Deferred Policy Acquisition Costs


View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry
Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.